Rchr
J-GLOBAL ID:201801020776667861   Update date: Jan. 15, 2026

Sato Tomohiro

サトウ トモヒロ | Sato Tomohiro
Affiliation and department:
Research field  (2): Biological, health, and medical informatics ,  Pharmaceuticals - chemistry and drug development
Research keywords  (8): SBDD ,  hERG ,  cheminformatics ,  in silico drug discovery ,  cardiotoxicity ,  support vector machine ,  deep learning ,  machine learning
Research theme for competitive and other funds  (2):
  • 2023 - 2026 Construction of a predictive model for antigen-antibody interaction energies using the FMO database
  • 2013 - 2015 Drug side effect prediction based on the machine learning of small molecule-protein interaction profiles
Papers (27):
  • Yosuke Nishigaya, Shohei Takase, Tatsunobu Sumiya, Ko Kikuzato, Takashi Hiroyama, Yuki Maemoto, Komei Aoki, Tomohiro Sato, Hideaki Niwa, Shin Sato, et al. Discovery of potent substrate-type lysine methyltransferase G9a inhibitors for the treatment of sickle cell disease. European journal of medicinal chemistry. 2025. 293. 117721-117721
  • Shoichi Ishida, Tomohiro Sato, Teruki Honma, Kei Terayama. Large language models open new way of AI-assisted molecule design for chemists. Journal of Cheminformatics. 2025. 17. 1
  • Tatsuya Yoshizawa, Shoichi Ishida, Tomohiro Sato, Masateru Ohta, Teruki Honma, Kei Terayama. A data-driven generative strategy to avoid reward hacking in multi-objective molecular design. Nature Communications. 2025. 16. 1
  • Ken-Ichi Takayama, Tomohiro Sato, Teruki Honma, Minoru Yoshida, Satoshi Inoue. Inhibition of PSF activity overcomes resistance to treatment in cancers harboring mutant p53. Molecular cancer therapeutics. 2024. 24. 3. 370-383
  • Yosuke Nishigaya, Shohei Takase, Tatsunobu Sumiya, Tomohiro Sato, Hideaki Niwa, Shin Sato, Akiko Nakata, Seiji Matsuoka, Yuki Maemoto, Noriaki Hashimoto, et al. Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment. Bioorganic & medicinal chemistry letters. 2024. 110. 129856-129856
more...
MISC (10):
  • 小田島大貴, 宮川柊兵, 半田佑磨, 古石誉之, 米持悦生, 佐藤朋広, 幸瞳, 本間光貴, 高谷大輔, 上村みどり, et al. Study of novel inhibitors of m-Glu5 using fragment molecular orbital method. 日本薬学会年会要旨集(Web). 2024. 144th
  • 小田島大貴, 宮川柊兵, 半田佑磨, 古石誉之, 米持悦生, 佐藤朋広, 幸瞳, 本間光貴, 高谷大輔, 上村みどり, et al. フラグメント分子軌道法を活用した代謝型グルタミン酸受容体5阻害剤の分子設計. 構造活性相関シンポジウム講演要旨集(CD-ROM). 2023. 51st
  • 神坂紀久子, 渡邉千鶴, 高谷大輔, 原田俊幸, 佐藤朋広, 幸瞳, 本間光貴. FMO法に基づく相互作用記述子を用いたp38MAPキナーゼの阻害剤活性予測. 構造活性相関シンポジウム講演要旨集. 2020. 48th (CD-ROM)
  • 原田俊幸, 原田俊幸, 渡邉千鶴, 森脇寛智, 神坂紀久子, 原田祐希, 佐藤朋広, 高谷大輔, 本間光貴. FMO and ML based QSAR Approach for Aurora Kinase Inhibitors. 構造活性相関シンポジウム講演要旨集. 2019. 47th (CD-ROM)
  • 幸瞳, 佐藤朋広, 小倉圭司, 本間光貴. ドッキングシミュレーションと部位特異的変異導入結果を用いたhERG阻害剤結合に関与するアミノ酸残基の解析. 構造活性相関シンポジウム講演要旨集. 2017. 45th
more...
Patents (1):
  • Preparation of 4-​[3-​(3-​pyridyl)​-​4-​pyrazolyl]​pyrimidin-​2-​amine derivatives as BMP-​signal pathway inhibitors
Books (1):
  • in silico創薬におけるスクリーニングの高速化・高精度化技術
    技術情報協会 2018 ISBN:4861046882
Lectures and oral presentations  (4):
  • Customizing applicability domain of a machine learning model using transfer learning
    (MOE Forum 2021 2021)
  • Development of an informatics system for predicting cardiotoxicity: 5. Quantitative model for hERG blocking small molecules based on the integrated database
    (CBI Annual meeting 2018 2018)
  • Adverse effect prediction by random forests model using polypharmacological profile of a small compound
    (CBI Annual meeting 2015 2015)
  • インシリコによるポリファーマコロジー予測技術の変遷
    (第17回創薬インフォマティクス研究会 2013)
Work history (3):
  • 2021/07 - 現在 Yokohama City University Graduate School of Medical Life Science Project associate professor
  • 2012/04 - 2021/06 RIKEN Research scientist
  • 2010/03 - 2012/03 RIKEN postdoctoral researcher
Awards (1):
  • 2021/11 - 日本薬学会構造活性相関部会 構造活性相関シンポジウム優秀発表賞(ポスター) 転移学習を用いた活性予測モデルの新規化合物シリーズに対するモデル適用性の改善
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page